Growing At A CAGR Of 15.7%, 3D Cell Culture Industry To Reflect Impressive Growth In Healthcare Sector.
Seeking Alpha Analyst Since 2014
#Healthcare Consultant focusing on #TeleHealth #TeleMedicine #PatientPortals #CVIS #HCIT #MedicalRobots #Vaccines #MedicalDevices #WirelessHealth #Biotechnology
- Revenue Mapping-Based Market Estimation.
- Who are the top 10 players operating in the global 3D Cell Culture market?
- What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
The growth of 3d cell culture market is driven mainly by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to restrain the growth of this market during the forecast period.
3D Cell Culture Market Dynamics: Impact Analysis
1. Revenue Mapping-Based Market Estimation
2. Geographic Growth Opportunities
3. Focus on Developing Alternatives to Animal Testing
4. Personalized Medicine
5. Increasing Incidence of Chronic Diseases
6. Microfluidics-Based 3D Cell Culture
The global 3D cell culture market size is projected to reach USD 1,846 million in 2024 from USD 892 million in 2019, at a CAGR of 15.7%.
Key Questions Addressed in The Report:
1. Who are the top 10 players operating in the global 3D Cell Culture market?
2. What are the drivers, restraints, opportunities, and challenges in the 3D Cell Culture Industry?
3. What are the opportunities for stakeholders and provide details of the competitive landscape for key players?
4. What will be growth of 3D Cell Culture in North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa?
Download PDF Brochure:
Cancer and Stem Cell Research Segment:
Based on application, the 3D cell culture market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. The cancer & stem cell research segment accounted for the largest share of the market in 2018 and is expected to register the highest CAGR during the forecast period. The increasing prevalence of cancer and significant funding for cancer research are major factors driving the growth of this application segment.
Pharmaceuticals and Biotechnology Companies:
Based on end user, the market is segmented into pharmaceutical & biotechnology companies, research institutes, the cosmetics industry, and other end users. Pharmaceutical & biotechnology companies accounted for the largest share of the market in 2018. The presence of a large number of pharmaceutical & biotechnology companies, an increase in R&D spending in these companies, and the growing preference for alternative testing models over animal techniques are the key market drivers in this end-user segment.
North America and Europe are the Largest Revenue Generating Regions:
North America commanded the largest share of the market due to the increasing incidence of cancer and the presence of a well-established pharmaceutical & biotechnology industry.
Europe is expected to grow at the highest CAGR during the forecast period. The growth of the market in Europe is attributed to the growth of its pharmaceutical and biotechnology industry, recent commercialization of microfluidics-based products, the increasing presence of major market players, and a large number of research activities conducted in the region.
Request Sample Report:
Key Players in 3d Cell Culture Industry:
Thermo Fisher Scientific (US), Corning Incorporated (US), Merck KGaA (Germany), Lonza AG (Switzerland), REPROCELL Incorporated (Japan), TissUse (Germany), InSphero (Switzerland), Synthecon (US), 3D Biotek (US), CN Bio (UK), Hamilton Company (US), MIMETAS (Netherlands), Emulate (US), Hµrel Corporation (US), QGel SA (Switzerland), SynVivo (US), Advanced BioMatrix (US), Greiner Bio-One International (Austria), and PromoCell (Germany).
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.